An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis

Vilar, Mônica Magno; Barrientos, Frank; Almeida, Marília Sirianni dos Santos; Thaumaturgo, Nilton; Simpson, Andrew; Garratt, R.C.; Tendler, Míriam

doi:10.1016/s0264-410x(03)00300-1

Cited by 41 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A B-cell epitope of 9B antigen, peptides from SG3PDH or from Sm-37-GAPDH together with Sm-10-DLC were able to induce partial protective immunity in the murine model (Tarrab-Hazdai et al 1998, Argiro et al 2000, Tallima et al 2003. Regarding Sm14 and paramyosin, only B-cell epitopes, different from the peptides described in this study, have been previously identified (Nara et al 1997, Vilar et al 2003.…”

Section: Discussionmentioning

confidence: 51%

Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells

Fonseca

Cunha‐Neto

Kalil

et al. 2004

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 51%

Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells

Fonseca

Cunha‐Neto

Kalil

et al. 2004

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

“…Fatty acid-binding proteins are among the characterized common proteins between both worms and exploited as a potential dualvaccine (Ramajo et al 2001;Vilar et al 2003;Ramos et al 2009). Recently, a proteomic-based approach identified 28 immunoreactive proteins that are common to both adult F. hepatica and S. mansoni.…”

Section: Introductionmentioning

confidence: 99%

Significance of a common 65 kDa antigen in the experimental fasciolosis and toxoplasmosis

Shaapan

Toaleb²,

Abdel-Rahman³

2013

J Parasit Dis

View full text Add to dashboard Cite

In the current study, cross-reaction between two important zoonotic parasites; extracellular helminthes Fasciola gigantica and intracellular protozoa Toxoplasma gondii was proved by enzyme linked immunosorbent assay. Five antigens were used to identify and compare the cross-binding activities in the prepared antisera. Two F. gigantica antigens; adult flukes (FgA) and eggs (FgEA) were used to detect IgG in T. gondii naturally infected human sera (TgIHS) and experimentally infected sera of sheep (TgISS), mice (TgIMS) and rats (TgIRS). Three types of T. gondii antigens; RH (TgRHA), local sheep isolate (TgLA) and ME49 isolate (TgMEA) were used to detect cross binding activities in F. gigantica experimental infected rabbit sera (FgIRS) and F. gigantica naturally infected bovine sera (FgIBS). The cross-binding activities in the prepared antisera were strongly directed towards FgA and TgLA rather than the other antigens. The characterization of the five antigens using SDS-PAGE showed 4 common bands of FgA and TgLA; 165, 97, 76, and 65 kDa. While two common bands were observed between TgRHA, TgMEA and FgA; 165, and 65 kDa. Whereas, two common bands found between three types of T. gondii antigens and FgEA were identified; 165 and 65 kDa. The immunogenic cross-reactive bands between FgA and TgLA with F. gigantica infected bovine sera were identified by immunoblot. In FgA, the common immunogenic bands were 165, 65 and 14 kDa. While in TgLA, common immunogenic bands were 165 and 65 kDa. Whereas, the common immunogenic band between FgA and TgLA identified with T. gondii experimentally infected sheep sera was 65 kDa. The current research proves cross reaction between F. gigantica and T. gondii. One common band of 65 kDa showed broad immunogenic cross-reactivity with the developed antisera raising the prospect of being putative common immunodiagnostic candidate of both infections.

show abstract

“…Second, bacterial strains can be converted into convenient and low cost cellular factories for production of bioactive molecules such as proteins, polysaccharides and nucleic acids. Such compounds can be purified by genetically modified strains and incorporated as antigens into subunit-based vaccine formulations (Vilar et al 2003). Finally, some bacterial species can be genetically modified in order to become live carriers delivered either by parenteral or, preferentially, by mucosal routes, of passenger antigens derived from one or several pathogens, either as intact proteins or peptides genetically fused to host bacterial proteins (Medina andGuzman 2001, Curtiss et al 1989).…”

mentioning

confidence: 99%

Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors

Ferreira

Schumann

2005

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

Bacillus subtilis and some of its close relatives have a long history of industrial and biotechnological applications. Search for antigen expression systems based on recombinant B. subtilis strains sounds attractive both by the extensive genetic knowledge and the lack of an outer membrane, which simplify the secretion and purification of heterologous proteins. More recently, genetically modified B. subtilis spores have been described as indestructible delivery vehicles for vaccine antigens. Nonetheless both production and delivery of antigens by B. subtilis strains face some inherent obstacles, as unstable gene expression and reduced immunogenicity that, otherwise, can be overcome by already available gene technology approaches. In the present review we present the status of B. subtilis-based vaccine research, either as protein factories or delivery vectors, and discuss some alternatives for a better use of genetically modified strains.

show abstract

An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis

Cited by 41 publications

References 25 publications

Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells

Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells

Significance of a common 65 kDa antigen in the experimental fasciolosis and toxoplasmosis

Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors

Contact Info

Product

Resources

About